DAFNA Capital Management »

Lexeo Therapeutics shares owned by DAFNA Capital Management

Quarter-by-quarter ownership of Lexeo Therapeutics (LXEO) shares owned by DAFNA Capital Management from 13F filings

Historical chart of DAFNA Capital Management investment in Lexeo Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Lexeo Therapeutics held by DAFNA Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Lexeo Therapeutics by DAFNA Capital Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $2.3M 251k 9.04

More positions owned by DAFNA Capital Management

Spdr S&p Biotech Etf Etf (XBI)
Stereotaxis Com New (STXS)
Revolution Medicines (RVMD)
Cytokinetics Com New (CYTK)
Merus N V (MRUS)
AtriCure (ATRC)
Ideaya Biosciences (IDYA)
Ishares Nasdaq Biotech Indx Etf (IBB)
Ascendis Pharma A/s Sponsored Adr (ASND)
Axogen (AXGN)
Blueprint Medicines (BPMC)
Xenon Pharmaceuticals (XENE)
Day One Biopharmaceuticals I (DAWN)
Syndax Pharmaceuticals (SNDX)
Biohaven (BHVN)

View all positions for DAFNA Capital Management

Top funds holding Lexeo Therapeutics

Henderson Group
Citadel Advisors
Omega Fund Management
Eventide Asset Management
BlackRock
Frazier Life Sciences Management
Blackstone Group
Novo A/S
Woodline Partners
Vestal Point Capital
BlackRock
Braidwell
Vanguard Group
Siren
Geode Capital Management

View all funds holding Lexeo Therapeutics